Last $9.01 USD
Change Today -0.04 / -0.44%
Volume 20.5K
DPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

dipexium pharmaceuticals inc (DPRX) Snapshot

Open
$9.08
Previous Close
$9.05
Day High
$9.14
Day Low
$8.85
52 Week High
03/13/14 - $15.86
52 Week Low
05/15/14 - $8.00
Market Cap
76.9M
Average Volume 10 Days
12.3K
EPS TTM
--
Shares Outstanding
8.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIPEXIUM PHARMACEUTICALS INC (DPRX)

Related News

No related news articles were found.

dipexium pharmaceuticals inc (DPRX) Related Businessweek News

No Related Businessweek News Found

dipexium pharmaceuticals inc (DPRX) Details

Dipexium Pharmaceuticals, LLC operates as a biopharmaceutical company that develops and commercializes, pexiganan, a small peptide anti-infective agent. It provides Locilex, a small peptide topical antibiotic for the treatment of mild and moderate skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds, and nasal colonization of methicillin-resistant staphylococcus aureus. The company was founded in 2010 and is based in White Plains, New York.

2 Employees
Last Reported Date: 03/13/14
Founded in 2010

dipexium pharmaceuticals inc (DPRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $219.3K
Co-Founder, Executive Chairman and Managing P...
Total Annual Compensation: $219.3K
Compensation as of Fiscal Year 2013.

dipexium pharmaceuticals inc (DPRX) Key Developments

Dipexium Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Update on Operational Progress

Dipexium Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the three months ended June 30, 2014, the company reported a net loss of approximately $3.921 million, compared to $0.363 million for the three months ended June 30, 2013, an increase of $3.5 million, primarily due to a $2.5 million increase in research and development expenses and a $1.0 million increase in general and administrative expenses. Loss from operations was $3.921 million against $0.363 million a year ago. Basic and diluted loss per share was $0.46 against $0.08 a year ago. For the six months ended June 30, 2014, the company reported a net loss of approximately $6.464 million, compared to $0.770 million for the six months ended June 30, 2013, an increase of $5.7 million, primarily due to a $4.3 million increase in research and development expenses and a $1.4 million increase in general and administrative expenses. Loss from operations was $6.464 million against $0.770 million a year ago. Basic and diluted loss per share was $0.90 against $0.17 a year ago. Net cash used in operating activities for the six months ended June 30, 2014 was $5.7 million. The company provided an update on operational progress. The company remains on its stated timeline to complete enrollment in the OneStep-1 and OneStep-2 pivotal phase 3 clinical trials in the first quarter of 2015 and file a new drug application (NDA) for Locilex(R) in the second half of 2015. In July, Dipexium announced the initiation of patient enrollment in OneStep-1 and OneStep-2, the Company's pivotal phase 3 trials of Locilex(R) for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI). These trials remain on track to complete enrollment in the first quarter of 2015. Also in July, the company reported the successful completion of DPX-110, a phase 1 skin irritation study of Locilex(R) in healthy adult volunteers. Results demonstrated that Locilex(R) is not a topical irritant. There was no statistical difference between Locilex(R), vehicle cream, and the negative control on intact or abraded skin. In the second quarter, the company initiated DPX-120, a phase 1 skin sensitization study of Locilex(R). Patient enrollment in the study was completed in July, and the Company expects to complete the study in the fourth quarter of 2014. Finally, during the second quarter, the Company initiated activities related to the preparation of a new drug application (NDA) for Locilex(R).

Dipexium Pharmaceuticals, LLC Initiates Pivotal Phase 3 Clinical Trial of Locilex(R) in Patients with Mild Infections of Diabetic Foot Ulcers

Dipexium Pharmaceuticals Inc. announced it has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex(R) (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex(R)'s pivotal Phase 3 clinical trial program in Mild DFI. OneStep-1 and OneStep-2 are identical, double-blind, placebo-controlled clinical trials conducted simultaneously that will each enroll approximately 180 patients at 20 separate centers in the United States. The primary objective is to establish the clinical superiority and safety of topical Locilex(R) plus standard local wound care as compared to placebo cream plus standard local wound care, in the treatment of Mild DFI. Patients will be randomized 1:1 to receive either topical Locilex(R) plus standard local wound care or placebo cream plus standard local wound care for 14 days, with final evaluation at day 28. The primary endpoint of the trials is clinical response, which is defined as infection resolved per the judgment of each treating physician using the 2012 Infectious Disease Society of America (IDSA) Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Secondary endpoints include microbiological success, which is defined as complete microbiological response, as well as the incidence and severity of adverse events.

Dipexium Pharmaceuticals, LLC Announces Completion of Phase 1 Skin Irritation Trial of Locilex(R)

Dipexium Pharmaceuticals Inc. announced successful completion and initial results of DPX-110, a Phase 1 skin irritation clinical trial of Locilex(R) (pexiganan cream 0.8%), the company's novel, broad-spectrum topical antibiotic peptide. Dipexium conducted DPX-110 and the company is conducting DPX-120, a Phase 1 skin sensitization clinical trial, in parallel with two required pivotal Phase 3 clinical trials for Locilex(R). The Company's pivotal Phase 3 clinical program is subject to a Special Protocol Assessment (SPA) agreement with FDA. DPX-110 was a single-center, double-blind study in healthy adult subjects with the primary objective of evaluating the cumulative skin irritation observed with Locilex(R) and vehicle (placebo) topical cream following an extended period of continuous exposure. Volunteers received applications of Locilex(R), vehicle cream, a positive control, and a negative (low irritant) control, for 21 days on both intact and abraded skin. Visual skin irritation assessments were performed by trained and blinded evaluators using a well-established, FDA-recognized standardized rating scale. Forty-two subjects were enrolled and assessed for skin irritation. The results for positive and negative controls were those expected, indicating a successful trial. Study results demonstrated that Locilex(R), as well as vehicle cream, are not topical irritants. There was no statistical difference between Locilex(R), vehicle cream, and the negative control on intact or abraded skin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DPRX:US $9.01 USD -0.04

DPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DPRX.
View Industry Companies
 

Industry Analysis

DPRX

Industry Average

Valuation DPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIPEXIUM PHARMACEUTICALS INC, please visit www.dipexiumpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.